Future
in sight
Pioneering a bold new generation of advanced therapies that decipher the code behind vision loss - helping to restore sight, transform patient's lives
Our Collaborators
This constitutes our proprietary angiogenic operating system. We're validating the gene codes in the operating system for micro-vasculature regeneration.
We intend to use the gene signatures of Angicyte together with patient insights to define tractable therapeutic targets in a strategy to reboot the retinal micro-vasculature in patients.
The result will be that the visual system grows new, healthy blood vessels and permanently prevents vision loss caused by retinal ischemia.
AngiGenix™: the future of vascular genetic therapy
Learn more
What is Angicyte?
What POC data do we have for Angicyte?
What impact will Angicyte have?
Eye Disease
Diseases causing population-wide, irreversible vision loss, such as diabetic retinopathy and age-related macula degeneration, are rapidly increasing in countries across the world and will afflict 100 million people by 2040. The current standard of care is recognised as treating the symptoms but not the underlying cause of these diseases.
For many of these diseases the root cause of ischemia is poor blood supply to the retina, the most metabolically active tissue in the human body.
Pathological stages include microvascular dysfunction leading to capillary non-perfusion, vascular leakage and hypoxia-driven VEGF upregulation leading to neovascularisation. Collectively this leads to progressive and irreversible retinal damage, tissue degeneration and declining visual acuity
Progressive vision loss is an enormous burden on health care providers which is expected to cost over $400 billion per annum by 2040. This is driving demand for innovative, yet cost-effective therapies for these diseases.
Current therapies for ischemic retinopathies involve repeated injections or destructive laser treatment. These treatments address the consequence of ischemia, such as the neovascularisation and show limited durability, poor efficacy and do not work in a significant proportion of the diverse population. Whereas our therapies are different, they target the restoration of normal micro-vascular supply to the retina, restoring perfusion, vitality, thereby preventing the onset of retinal dystrophy and vision loss.
Contact Us.
We are developing advanced therapies that drive regeneration of the micro-vasculature in the retina. Building on research from Queen’s University Belfast, we have established and patented a robust process for extracting and scaling a rare type of blood cell that promotes vasculature regeneration. This cell technology we call Angicyte®. It is the blueprint – the hardware – for specifying our therapeutic designs for treating vision loss caused by ischaemia.
We can manufacture these cells, called Angicyte®, at the scale and quality required for cell transplantation to treat vision loss caused by ischaemia.
If high-performance Angicyte® is the hardware, our analysis of its transcriptome represents its software – its operating system – which we call AngiGenix™.
Genetic analysis of Angicyte® – AngiGenix™ – affords a unique opportunity to develop new genetic therapies targeting a patient’s own vascular cells.